Positive Phase 3 Results for Novel Schizophrenia Drug
The investigational agent xanomeline-trospium (KarXT, Karuna Therapeutics), which combines a muscarinic receptor agonist with an anticholinergic agent, helps improve psychosis
Read moreThe investigational agent xanomeline-trospium (KarXT, Karuna Therapeutics), which combines a muscarinic receptor agonist with an anticholinergic agent, helps improve psychosis
Read moreRare gene variants are associated with a reduced risk for multiple types of liver disease, including cirrhosis, researchers say. People
Read morePeople with elevated levels of protein prostasin seem to have a higher risk of developing diabetes and dying from cancer,
Read moreLipoprotein(a) has long been thought to be a potential marker of aortic valve disease, and the population-based Rotterdam Study in
Read moreMany women with symptoms of menopause are turning to cannabis for help, researchers have found, despite a lack of evidence
Read moreAre Mini Robots Coming to Your Hospital? Super-small robot crabs could one day perform delicate surgical tasks, like repairing small
Read moreImagine being wheeled into the operating room where your surgical team awaits – the surgeon, the anesthesiologist, and … a
Read moreThe US Food and Drug Administration (FDA) has approved roflumilast 0.3% cream for the topical treatment of plaque psoriasis, “including
Read moreFor people with peripheral artery disease (PAD), even short walks can be exercises in excruciation. But a new study published
Read moreTherapeutic plasma exchange (TPE) is safe, well-tolerated, and improves symptoms in most patients with stiff-person spectrum disorders (SPSD), a group
Read more